Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the management of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulator...
متن کاملHow Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatm...
متن کاملAlemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for...
متن کاملSystematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
OBJECTIVE Multiple sclerosis (MS) is a chronic, neurodegenerative autoimmune disorder affecting the central nervous system. Relapsing-remitting MS (RRMS) is the most common clinical form of MS and affects ∼85% of cases at onset. Highly active (HA) and rapidly evolving severe (RES) RRMS are 2 forms of RRMS amenable to disease-modifying therapies (DMT). This study explored the efficacy of fingoli...
متن کاملNatalizumab for relapsing multiple sclerosis.
To the Editor: As Ropper pointed out in his editorial (March 2 issue),1 the three articles on the use of natalizumab in that issue of the Journal are pivotal, but his conclusion that natalizumab is “a potent treatment for multiple sclerosis” may be too sanguine. The similar entry criteria, treatment, and methods of analysis permit clinically useful conclusions to be drawn from the placebocontro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advances in Therapy
سال: 2019
ISSN: 0741-238X,1865-8652
DOI: 10.1007/s12325-019-01186-z